The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Mepolizumab effectiveness and identification of super-responders in severe asthma
Open accessAbstract
Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population. The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia. Patients (n=309) with severe eosinophilic asthma (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12 months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590 cells·µL−1. Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%. Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29–0.41); p<0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33–0.63); p<0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline. Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Development of the asthma control test
Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., Murray, J. J., & Pendergraft, T. B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.008 · Cited by 2,906
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Cited by
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Eosinophils in Health and Disease: A State-of-the-Art Review
Wechsler, M. E., Munitz, A., Ackerman, S. J., Drake, M. G., Jackson, D. J., Wardlaw, A. J., Dougan, S. K., Berdnikovs, S., Schleich, F., Matucci, A., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.025 · Cited by 312
Asthma remission: what is it and how can it be achieved?
Thomas, D., McDonald, V. M., Pavord, I. D., & Gibson, P. G. (2022) · European Respiratory Journal · doi:10.1183/13993003.02583-2021 · Cited by 274
Self-citation‘Breathing Fire’: Impact of Prolonged Bushfire Smoke Exposure in People with Severe Asthma
Beyene, T., Harvey, E. S., Van Buskirk, J., McDonald, V. M., Jensen, M. E., Horvat, J. C., Morgan, G. G., Zosky, G. R., Jegasothy, E., Hanigan, I., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127419 · Cited by 35
Self-citation
Metadata
- Authors
- Harvey, E. S., Langton, D., Katelaris, C., Stevens, S., Farah, C. S., Gillman, A., Harrington, J., Hew, M., Kritikos, V., Radhakrishna, N., Bardin, P., Peters, M., Reynolds, P. N., Upham, J. W., Baraket, M., Bowler, S., Bowden, J., Chien, J., Chung, L. P., Grainge, C., Jenkins, C., Katsoulotos, G. P., Lee, J., McDonald, V. M., Reddel, H. K., Rimmer, J., Wark, P. A. B., & Gibson, P. G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-03-05
- Volume
- 55
- Issue
- 5
- Pages
- 1902420
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W3009509122
- Cited by
- 190
- References
- 3
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.